Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 150
- Registration Number
- NCT05250973
- Locations
- 🇺🇸
West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇬🇧University College Hospital, London, United Kingdom
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT05218603
- Locations
- 🇪🇸
Hospital Quirón Sagrado Corazón, Barcelona, Spain
🇪🇸Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain
🇪🇸Hospital Ruber Juan Bravo 39, Madrid, Spain
Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.
- Conditions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Karin B. Ø. Dieperink
- Target Recruit Count
- 10
- Registration Number
- NCT05163405
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 51
- Registration Number
- NCT05147493
- Locations
- 🇬🇷
Anticancer Oncology Hospital of Athens "Agios Savvas", Athens, Greece
🇬🇷University General Hospital of Ioannina, Ioannina, Greece
🇬🇷Anticancer Hospital of Thessaloniki "Theageneio", Thessaloniki, Greece
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
- Conditions
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Hospital General de Mexico
- Target Recruit Count
- 56
- Registration Number
- NCT05137860
- Locations
- 🇲🇽
Hospital General de México "Dr. Eduardo Liceaga", Mexico City, Mexico
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 317
- Registration Number
- NCT05137054
- Locations
- 🇺🇸
Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 43
- Registration Number
- NCT05123131
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇮🇪Beaumont Hospital, Dublin, Ireland
🇮🇪Mater Misericordiae University Hospital, Dublin, Ireland
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 587
- Registration Number
- NCT05083169
- Locations
- 🇺🇸
Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Tanja Andrea Gruber
- Target Recruit Count
- 22
- Registration Number
- NCT04996160
- Locations
- 🇺🇸
Lucile Packard Children's Hospital Stanford, Stanford, California, United States
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 864
- Registration Number
- NCT04975997
- Locations
- 🇺🇸
Ohio Health Corporation, Columbus, Ohio, United States
🇺🇸MetroHealth Medical Center - Main Campus, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.